Mateusz Opyrchal named inaugural Vera Bradley Foundation Scholar in Breast Cancer Discovery at IU

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

June 05, 2026

Vol.52 No.22

Drugs & Targets

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Stage 4 breast cancer has increased in incidence and proportion over the last decade

Researchers found that cases of stage 4 breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses, according to findings from an observational study.

May 15, 2026

Vol.52 No.19

Drugs & Targets

FDA clears AI digital pathology risk stratification tool in breast cancer

FDA cleared ArteraAI Breast, a multimodal AI-based prognostic and predictive cancer test, for use in patients with early-stage, hormone receptor-positive HER2-negative invasive breast cancer.

May 15, 2026

Vol.52 No.19

In Brief

IU Cancer Center Chuckstrong Tailgate Gala raises more than $900,000

The 14th annual Chuckstrong Tailgate Gala raised more than $900,000 for research at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

April 24, 2026

Vol.52 No.16

Cancer Policy

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

April 17, 2026

Vol.52 No.15

By Jacquelyn Cobb

Mateusz Opyrchal named inaugural Vera Bradley Foundation Scholar in Breast Cancer Discovery at IU

YOU MAY BE INTERESTED IN

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

Stage 4 breast cancer has increased in incidence and proportion over the last decade

FDA clears AI digital pathology risk stratification tool in breast cancer

IU Cancer Center Chuckstrong Tailgate Gala raises more than $900,000

FDA adds stereotactic breast biopsy needles to the shortage list

Renew today!

Subscriber content

Never miss an issue!

Login